Abstract
Observing the entire small bowel is difficult due to the presence of complex loops and a long length. Capsule endoscopy (CE) provides a noninvasive and patient-friendly method for visualizing the small bowel and colon. Small bowel capsule endoscopy (SBCE) has a critical role in the diagnosis of small bowel disorders through the direct observation of the entire small bowel mucosa and is becoming the primary diagnostic tool for small bowel diseases. Recently, colon capsule endoscopy (CCE) was also considered safe and feasible for obtaining sufficient colonic images in patients with incomplete colonoscopy, in the absence of bowel obstruction. This review article assesses the current status of CE in terms of the diagnostic yield and the clinical impact of SBCE in patients with obscure gastrointestinal bleeding, who have known or suspected Crohn’s disease, small bowel tumor and inherited polyposis syndrome, celiac disease, and those who have undergone CCE.
Highlights
It is difficult to directly examine the small bowel because of its length, and it is hard to use conventional endoscopic devices owing to the complex loops and length of the small bowel [1,2]
obscure gastrointestinal bleeding (OGIB) accounted for 66% of all Small bowel capsule endoscopy (SBCE) indications, and the remaining SBCE indications were distributed between chronic abdominal symptoms (10.6%), Crohn’s disease (CD) (10.4%), small bowel tumor (3.5%), and celiac disease (1.7%) [10,11]
We evaluated the current status of Capsule endoscopy (CE) in terms of its diagnostic yield and the clinical impact of SBCE on patients with gastrointestinal bleeding, who have known or suspected CD, small bowel tumor and inherited polyposis syndrome, celiac disease, and those who have undergone colon capsule endoscopy (CCE)
Summary
It is difficult to directly examine the small bowel because of its length (average length, 575 cm at the age of 20), and it is hard to use conventional endoscopic devices owing to the complex loops and length of the small bowel [1,2]. The range of the small bowel that could be observed by push-enteroscopy was limited, despite considerable patient discomfort [3]. The diagnostic yields of these imaging modalities were very low (push-enteroscopy, 35%, SBR, 37%) [4,5]. SBCE is indicated for small bowel tumors and inherited polyposis syndromes, celiac disease, chronic diarrhea, and chronic abdominal pain, and for clarifying abnormal small intestinal findings from other imaging examinations. OGIB accounted for 66% of all SBCE indications, and the remaining SBCE indications were distributed between chronic abdominal symptoms (10.6%), CD (10.4%), small bowel tumor (3.5%), and celiac disease (1.7%) [10,11]. We evaluated the current status of CE in terms of its diagnostic yield and the clinical impact of SBCE on patients with gastrointestinal bleeding, who have known or suspected CD, small bowel tumor and inherited polyposis syndrome, celiac disease, and those who have undergone CCE
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
